Catalyst Biosciences Культура компании

Mr. Fletcher Payne has been the Chief Financial Officer at Catalyst Biosciences, Inc. since January 2015. Mr. Payne has over 20 years of business and financial experience, in both start-up and Fortune 500 companies. He served as the Chief Financial Officer of Pathwork Diagnostics, Inc. since October 2008. He served as a Vice President and Chief Financial Officer at Plexxikon Inc., a biopharmaceutical company. Prior to Plexxikon, he worked for CytomX, Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Abgenix, Sun Microsystems and IBM. He is a graduate of UC Berkeley's Haas School of Business with a BS in Business Administration.

Dr. Jack Nguyen, PhD Co-Founded Catalyst Biosciences, Inc. Dr. Nguyen served as Director of Research at Adamas Pharmaceuticals, Inc. He has expertise knowledge in molecular biology, biochemistry, and cell biology. Prior to Catalyst, he was a Postdoctoral Fellow in the Laboratory of Dr. James Wells at Sunesis Pharmaceuticals, where he worked on identifying small molecule activators of apoptosis as cancer therapeutics. Dr. Nguyen was also a Damon Runyon-Walter Winchell Postdoctoral Fellow. Dr. Nguyen received his Ph.D. in Biophysics from the University of California, San Francisco, where he was a National Science Foundation Predoctoral Fellow.

Dr. Charles S. Craik, Ph.D., is a Professor in the Departments of Pharmaceutical Chemistry, Cellular & Molecular Pharmacology and Biochemistry & Biophysics at the University of California at San Francisco and is also the founder and Director of the Chemistry and Chemical Biology Graduate Program. He served as a Scientific Advisor of Ironwood Pharmaceuticals, Inc. Dr. Craik co-founded Catalyst Biosciences, Inc. in 2003 and served as its Chairman of the Board and President. He joined the UCSF faculty in 1985. He serves as Chairman of Scientific Advisory Board of Catalyst Biosciences, Inc. He served as Chairman and Member of Advisory Board at Catalyst Biosciences, Inc. He serves as Scientific Advisor of Protagonist Therapeutics, Inc. and Ironwood Pharmaceuticals Inc. He serves as a Member of Scientific Advisory Board at CytomX Therapeutics, Inc. He serves on advisory panels for the National Institutes of Health, the National Science Foundation, the National Academy of Sciences and the Department of Energy. Dr. Craik serves as an Associate Editor of the Journal Protein Engineering and has co-authored two books. He has organized several international meetings on topics including Protein Engineering, Drug Discovery and The Biology of Proteolysis. He has published over 200 research articles on various biochemical topics. He focuses on the Chemical Biology of proteolytic enzymes and their natural inhibitors. He is a Member of Scientific Advisory Board at Protagonist Pty Ltd. Dr. Craik received his Ph.D. in Chemistry from Columbia University in New York and carried out his postdoctoral research at UCSF with Dr. William Rutter.

Dr. Howard Levy, M.B.B.Ch., Ph.D., M.M.M. has been the Chief Medical Officer at Catalyst Biosciences, Inc. since April 18, 2016. Dr. Levy is Principal Investigator at research institutions and clinical study development teams for pharmaceutical companies. Dr. Levy has more than 25 years of experience. Since 2010, Dr. Levy has advised various biotechnology firms on clinical and drug development strategy. Dr. Levy served as the Chief Medical Officer at Inspiration Biopharmaceuticals, Inc. since December 22, 2011 and also served as its Senior Vice President. He served as Chief Medical Officer of Sangart, Inc. and also served as its Chief Scientific Officer since joining it in December 2008. Prior to Sangart, he was employed by Novo Nordisk Inc in Princeton, New Jersey from February 2006 to November 2008. He served as Vice President, Clinical Research, Medical and Regulatory Affairs at Novo Nordisk Inc. and was responsible for clinical research of the hemostasis platform. He was a Principal Investigator of the successful PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial. Dr. Levy has designed and executed Phase I-IV studies of new pharmaceutical agents for Trauma, Intracranial Hemorrhage, Severe Sepsis, Acute Respiratory Distress Syndrome (ARDS), Hemophilia, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Pancreatitis, Serious Infections, Burns and Deep Venous Thrombosis prevention studies for over 20 years. He previously served as Chief of Critical Care Medicine, Medical Director of the Medical Intensive Care Unit and head of the Critical Care training program at the University of New Mexico in Albuquerque from 1989 to 2000. Dr. Levy served as an Associate Vice President at Novo Nordisk Inc. based in Princeton, New Jersey since February 2006 and was responsible for Clinical Research of the Hemostasis platform, Inflammation/Oncology, Growth Hormone and Hormone Therapy for menopause therapeutic areas, leading teams researching initial and additional indications for recombinant human activated Factor VII and derivatives and Factors VII, IX and XIII, Growth Hormone, systemic and topical Estrogens, anti-Interferon, anti-Interleukins and other biologic compounds. In October 2000, Dr. Levy moved to Eli Lilly and company as Medical Director Acute Care in the United States Medical Division of with responsibility for the Xigris (Activated Protein C), ReoPro and prasugrel teams, in the therapeutic areas of Severe Sepsis and Cardiovascular Disease. Dr. Levy serves as Member of Scientific Advisory Board at ZZ Biotech, LLC. He served as a Member of Advisory Board at Asahi Kasei Pharma America Corporation. He is a contributing author, consultant and manuscript reviewer to several publications and is a widely published author of medical articles. He is recognized with a number of awards. Dr. Levy was honored by nomination and election as a Fellow of the Royal College of Physicians in May 2002 and election to the International Health Expert Committee of the United States Pharmacopoeia (USP) for 2005-2010. He is a fellow of the American College of Chest Physicians (CHEST) for which he served as Governor of the Society of Critical Care Medicine for the State of New Mexico. Dr. Levy is a Critical Care and Pulmonary physician. He is board certified by the American Board of Internal Medicine and in Pulmonary Diseases and Critical Care Medicine and is a Certified Physician Executive. He is licensed to practice in New Mexico. Dr. Levy was awarded a BSc in Anatomy and Physiology in 1975 and MB BCh (Doctor of Medicine equivalent) in 1978, both from the University of Witwatersrand, Johannesburg, South Africa. He completed his residency in Internal Medicine in South Africa at the Johannesburg Hospital in 1985. He completed a Pulmonary and Critical Care Fellowship at the City of Hope/Veterans Administration Long Beach/University of Irvine, CA in 1989. Dr. Levy obtained his Ph D from the University of the Witwatersrand in 1996 and a Masters in Medical Management at Carnegie-Mellon in 2001.

Grant Blouse serves as the Vice President, Translational Research of Catalyst Biosciences. Grant started at Catalyst Biosciences in July of 2018. Grant is currently based in the San Francisco Bay Area.

Howard Levy serves as the Chief Medical Officer of Catalyst Biosciences. Howard started at Catalyst Biosciences in April of 2016. Howard is currently based in the Greater New York City Area.

Arwa Shurrab serves as the Vice President of Catalyst Biosciences. Arwa started at Catalyst Biosciences in November of 2017. Arwa is currently based in the Greater Los Angeles Area.

Faisal Shawwa serves as the Executive Director Finance & Senior Controller of Catalyst Biosciences. Faisal started at Catalyst Biosciences in November of 2018. Faisal is currently based in the San Francisco Bay Area.